Collectively, these observations have prompted interest in dose-escalated third-generation EGFR-TKIs as a potential, albeit non-standard, option for selected patients with EGFR ex20ins-mutant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.